1-4 of 4
Bin Xie
Close
Sort by
Journal Articles

A Novel Patient-Derived Xenograft Model IO-FIVE for Drug Discovery and Precision Medicine in Lymphoma and Leukemia Patients

Bin Xie, Chanjuan Jin, Yang Liu, Wei Hua, Zhenle Bi, Kaimeng Hu, Di Zhou, Yanan Zhao, Lintao Bi, Danyi Wen
Journal: Blood
Blood (2023) 142 (Supplement 1): 6121.
https://doi.org/10.1182/blood-2023-178997
Published: 2023
Journal Articles

Non-Interventional Observational Analysis of the Clinical Outcomes with IO-FIVE (Immune-Oncology Fast In Vivo Efficacy Test) in Lymphoma Patients

Chanjuan Jin, Bin Xie, Di Zhou, Yanan Zhao, Wei Hua, Zhenle Bi, Yang Liu, Kaimeng Hu, Lintao Bi, Danyi Wen
Journal: Blood
Blood (2023) 142 (Supplement 1): 6130.
https://doi.org/10.1182/blood-2023-181478
Published: 2023
Journal Articles

Real World Outcomes in Acute Myeloid Leukemia Patients Following Post Hematopoietic Stem-Cell Transplantation Maintenance Treatment with Midostaurin or Sorafenib: A US Retrospective Cohort Study

Lori Muffly, Christopher Young, Bin Xie, Alana Block, Maelys Touya, Bhavik J. Pandya
Journal: Blood
Blood (2022) 140 (Supplement 1): 8111–8112.
https://doi.org/10.1182/blood-2022-157964
Published: 2022
Journal Articles

Influence of Residual Normal Metaphases In Patients with Monosomal Karyotype.

Bin Xie, MD, PhD, Megan Othus, PhD, Bruno C. Medeiros, MD, Min Fang, M.D., Ph.D., Frederick R. Appelbaum, MD, Elihu H. Estey, MD
Journal: Blood
Blood (2010) 116 (21): 1671.
https://doi.org/10.1182/blood.V116.21.1671.1671
Published: 2010